Clinical trial
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
NCT06419205 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
- Lead sponsor
- Akebia Therapeutics
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 30, 2026
- Completion date
- February 29, 2028
- Enrollment
- 30 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
c3 (complement component 3) glomerulopathy, iga nephropathy, lupus nephritis (ln)